Trevena Inc. Daily Stock Analysis

Daily Stock Analysis, TRVN, Trevena Inc, priceseries

Trevena Inc. Daily Stock Analysis
Stock Information
Open
0.45
Close
0.43
High
0.45
Low
0.43
Previous Close
0.44
Daily Price Gain
-0.01
YTD High
0.64
YTD High Date
Jan 11, 2022
YTD Low
0.40
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.19
YTD Gain
-30.98%
52 Week High
2.31
52 Week High Date
Apr 15, 2021
52 Week Low
0.40
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.62
52 Week Gain
-79.02%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
5.88
Jan 17. 2017
6.20
10 Trading Days
5.39%
Link
LONG
Jan 31. 2017
6.98
Feb 14. 2017
7.44
10 Trading Days
6.62%
Link
LONG
Jul 11. 2017
2.38
Jul 21. 2017
2.68
8 Trading Days
12.65%
Link
LONG
Feb 4. 2019
1.12
Feb 20. 2019
1.44
11 Trading Days
28.27%
Link
LONG
Mar 15. 2019
1.55
Mar 25. 2019
1.63
6 Trading Days
5.32%
Link
LONG
Jun 17. 2019
1.11
Jun 20. 2019
1.17
3 Trading Days
5.41%
Link
LONG
Apr 23. 2020
0.68
May 29. 2020
1.21
25 Trading Days
79.42%
Link
LONG
Jun 15. 2020
1.33
Jun 26. 2020
1.60
9 Trading Days
19.98%
Link
LONG
Jul 24. 2020
1.98
Aug 6. 2020
2.44
9 Trading Days
23.31%
Link
LONG
Sep 9. 2020
1.74
Oct 12. 2020
3.06
23 Trading Days
75.64%
Link
LONG
Feb 3. 2021
2.37
Feb 12. 2021
2.57
7 Trading Days
8.32%
Link
Company Information
Stock Symbol
TRVN
Exchange
NasdaqGS
Company URL
http://www.trevenainc.com
Company Phone
6103548840
CEO
Maxine Gowen
Headquarters
Pennsylvania
Business Address
955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK, PA 19087
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001429560
About

Trevena, Inc. is a clinical stage biopharmaceutical company. It discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. The company product pipeline consists of TRV027, TRV130, TRV734, and Delta Opiod. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.

Description

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading